A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Study acronym: RELATIVITY-106
StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 14, 2026 Show 4 more changesShow less
    • Primary endpoints: 2 to 3
    • Enrollment target: 83 to 82
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: 6 to 7
  2. Enrollment target: 162 to 83
    • Trial status: Active, Not Recruiting to Completed
    • Primary completion date changed from estimate of Oct 15, 2025 to Jul 5, 2025
    • Study completion date changed from estimate of Nov 7, 2025 to Nov 18, 2025
    v29
  3. Study completion date: Dec 15, 2026 to Nov 7, 2025v28
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 64 to 61
    v27
  5. Primary completion date: Jun 4, 2024 to Oct 15, 2025
    • Study sites revised (64)
    v26
Show 24 earlier versionsHide 24 earlier versions
  1. Study sites revised (64)v25
  2. Study sites revised (64)v24
  3. Study sites revised (64)v23
  4. Study sites revised (64)v22
  5. Site details revised at 7 of 64 sitesv21
  6. Site details revised at 1 of 64 sitesv20
  7. Site details revised at 2 of 64 sitesv19
  8. Site details revised at 1 of 64 sitesv18
  9. Primary endpoints revised (2)
    • Secondary endpoints revised (6)
    • Site details revised at 4 of 64 sites
    v17
  10. Study sites: 63 to 64v16
  11. Site details revised at 5 of 63 sitesv15
  12. Site details revised at 2 of 63 sitesv14
  13. Primary completion date: Jan 3, 2025 to Jun 4, 2024
    • Study completion date: Jan 4, 2025 to Dec 15, 2026
    • Site details revised at 16 of 63 sites
    v13
  14. Start date: Jun 8, 2022 to May 5, 2022
    • Site details revised at 1 of 63 sites
    v12
  15. Start date: May 5, 2022 to Jun 8, 2022
    • Site details revised at 6 of 63 sites
    v11
  16. Study sites: 32 to 63v10
  17. Study sites: 31 to 32v9
  18. Study sites: 30 to 31v8
  19. Study sites: 27 to 30v7
  20. Study sites: 20 to 27v6
  21. Study sites: 10 to 20v5
  22. Study sites: 9 to 10v4
  23. Study sites: 6 to 9v3
  24. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 4 to 6
    • Start date changed from estimate of Apr 30, 2022 to May 5, 2022
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT05337137
Lead Sponsor Bristol-Myers Squibb
Conditions
(from sponsor)		 Carcinoma, Hepatocellular
Related terms Carcinoma, Hepatocellular, Liver Neoplasms
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov